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DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY COMMENTARIES
Clinical assessment of early brain function in infants with
congenital heart disease
MIRTHE J MEBIUS | AREND F BOS
Division of Neonatology, Beatrix Children’s Hospital, University Medical Center
Groningen, Groningen, the Netherlands.
doi: 10.1111/dmcn.13936
This commentary is on the original article by Hogan et al. on pages
1225–1231 of this issue.
Perinatal adverse events may disrupt neuronal structures
and connections in the developing brain. In such cases, it
has been hypothesized that functional outcome can be
improved by stimulating and activating spared corticospinal
tract axons, for example in infants with cerebral palsy.1
Improved outcomes following stimulation through activa-
tion of spared neuronal structures after brain injury could
also be considered for infants with congenital heart disease
(CHD). It has become increasingly clear that infants with
CHD are at risk of neurodevelopmental impairments.2 It is
therefore essential to identify these at-risk infants with
CHD as early as possible when plasticity of the brain is
the highest.
Hogan et al.3 used the Neonatal Intensive Care Unit
Network Neurobehavioral Scale (NNNS) to assess neu-
robehavioral integrity in 67 infants with various types of
CHD, before and after surgery. The NNNS is a standard-
ized assessment tool to evaluate at-risk infants and is asso-
ciated with neurodevelopmental outcome at 18 months in
drug-exposed neonates and in neonates born preterm.
Hogan et al. demonstrated that abnormal neurobehavioral
patterns are common in infants with CHD; furthermore,
they have distinctive neurobehavioral patterns in compar-
ison with other at-risk populations, such as drug-exposed
neonates.
Although the study by Hogan et al. is well performed
and reports interesting findings, there are several limita-
tions. First, they included a relatively small and very
heterogeneous study population. Various types of CHD
were included, almost one-third of the infants were born
preterm and more than one-quarter were diagnosed with a
genetic syndrome. The authors have analyzed differences
between these subgroups, but the study population was too
small to draw definite conclusions. Second, information on
clinical characteristics (such as mechanical ventilation), use
of medication (Prostaglandin E1, sedatives), and Apgar
scores at 5 minutes, was limited. All these characteristics
could have influenced the NNNS scores and should there-
fore be accounted for.
It is still unknown which tool is best to predict neurode-
velopmental outcome in infants with CHD. The NNNS is
promising since it is non-invasive and could be applied
immediately after birth. It would be interesting to investi-
gate whether the NNNS predicts neurodevelopmental out-
come in the infants studied by Hogan et al. Other tools
that seem promising in predicting neurodevelopmental
outcome of at-risk infants are magnetic resonance imaging
(MRI), the General Movements Assessment (according to
Prechtl’s method), amplitude-integrated electroencephalog-
raphy, and near-infrared spectroscopy.1,4 A recent system-
atic review reported that in infants born preterm the
NNNS was better for research purposes, while the General
Movements Assessment was better for clinical utility and
prediction of neurodevelopmental outcome.5 Additional
research is necessary to identify which tool is best to pre-
dict outcome in infants with CHD, especially since Hogan
et al. found distinctive neurobehavioral patterns before and
after surgery in these infants, in comparison with earlier
studies on preterm-born neonates and drug-exposed neo-
nates.
In conclusion, the study by Hogan et al. is of high clini-
cal relevance as it demonstrates that it is possible to iden-
tify abnormal neurobehavioral patterns immediately after
birth in infants with various types of CHD. Future studies
are necessary to assess whether abnormal neurobehavioral
patterns shortly after birth are associated with abnormal
neurodevelopmental outcomes later in life. Furthermore,
large multicenter studies should be conducted to allow for
risk stratification according to the type of CHD, and to
make a distinction between neonates born preterm and at
term with CHD, and with isolated and syndromal CHD.
Most importantly, we suggest a study of infants with CHD
be performed combining several assessment tools such as
(for example) the NNNS, the General Movements Assess-
ment, MRI, near-infrared spectroscopy, and amplitude-
integrated electroencephalography. This proposed study
should be aimed at optimizing the identification of infants
with CHD at risk of neurodevelopmental impairments,
who may benefit most from early intervention.
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Clinical biomarkers for assessing neurodevelopmental outcome of
infants born preterm
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This commentary is on the original article by Franckx et al. on pages
1232–1238 of this issue.
It is well recognized that children with cerebral palsy
(CP) often present with sensory deficits that limit proprio-
ception, stereognosis, and tactile discrimination. Recent
brain imaging studies have revealed that the neurophysio-
logical nexus for these deficits likely resides in the aber-
rant somatosensory cortical processing of the peripheral
stimulations arising from the hands and feet.1,2 It seems
logical that these somatosensory neuroimaging metrics
might provide a non-invasive, early biomarker for identi-
fying infants born preterm that are on course for adverse
neurodevelopmental outcomes. Uncovering the predictive
validity of the somatosensory neuroimaging measures
would be valuable for informing parents about the poten-
tial long-term trajectory of their child’s neurodevelop-
ment, and for identifying infants that may benefit from
alternative therapeutic approaches during critical develop-
mental windows.
The retrospective study by Franckx et al.3 aims to
advance our understanding of a battery of clinical assess-
ments (e.g. cranial ultrasound, magnetic resonance imaging
[MRI], somatosensory evoked potentials) in identifying the
long-term neurological outcome of infants born preterm at
risk of developmental disabilities. Their analysis suggests
that assessing the somatosensory cortical activity evoked
after simulating the tibial nerve has limited utility for pre-
dicting an infant’s future neurodevelopmental problems.
Rather, cranial ultrasound during the first 2 weeks of life
has a better ability to predict the likelihood that an infant
would have CP or a cognitive developmental delay.
Although these insights support the continued use of cra-
nial ultrasound, the somatosensory results should be inter-
preted with caution because they are in opposition to a
prior magnetoencephalography (MEG) study that suggests
the uncharacteristic somatosensory evoked potentials pre-
dicts the potential for problematic neuromotor develop-
mental outcomes in infants with a low birthweight.4
Potentially, measures of the evoked somatosensory cortical
activity used retrospectively may be of limited value because
electroencephalography measures can be strongly distorted
by the open fontanelle in the infant’s skull, while the MEG
neuromagnetic measurements are not.
Additional challenges reside in the ability to accurately
assess neural activity based on a sensor positioned over the
leg region of the somatosensory cortical topology (e.g. Cz).
Unfortunately, sensor (scalp) time series are plagued with
methodological limitations that affect accurate measures
from the source of neural activity (i.e. volume conduction).
Recent technological breakthroughs have resulted in the
development of whole-head infant specific MEG devices
that overcome these limitations. These ultramodern
devices and associated advanced beamforming algorithms
will likely provide conclusive evidence as to whether the
evoked somatosensory cortical activity provides a reliable
biomarker for assessing neurodevelopmental risk of infants
born preterm.
Reliable metrics for predicting the likelihood of an unchar-
acteristic neurodevelopmental trajectory during infancy
remains a pervasive Gordian knot in developmental medi-
cine. Untangling this knot is challenging given that differ-
ential outcomes arise from numerous internal and external
factors, including the developing brain’s enormous capacity
for neuroplasticity. The current best-practice guidelines
recommend that a combination of clinical assessments
(including MRI, Hammersmith Infant Neurological Exam-
ination, and General Movement Assessment) may lead to
better prediction of an infant’s neurodevelopmental
trajectory at or before 5 months of age.5 Furthermore, the
overarching consensus is that single time-point measure-
ments do not accurately capture an infant’s neurological
potential; but rather, repeated neurological and clinical
assessments, coupled with clinical reasoning, are more
likely to be prognostic.
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